Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 4;11(1):57.
doi: 10.1186/s40780-025-00466-x.

The effect of sertraline with or without propranolol on panic attacks in women: a controlled clinical trial

Sahar Rouhzendeh  1 , Zahra Mousavi  2 , Sepideh Mashayekh-Amiri  3 , Elnaz Shaseb  4 , Seyedeh Tahereh Mirmolaei  5 , Mojgan Mirghafourvand  6
Affiliations

The effect of sertraline with or without propranolol on panic attacks in women: a controlled clinical trial

Sahar Rouhzendeh et al. J Pharm Health Care Sci. .

Abstract

Background: The use of propranolol in the treatment of panic attacks has historically been widespread. However, there is insufficient precise evidence regarding the combination of propranolol with sertraline in this context. Panic attacks are a common health issue among women, significantly affecting their personal and social lives. Therefore, this study aimed to determine the effect of sertraline, with or without propranolol, on the severity of panic attack symptoms and depressive symptoms.

Methods: This randomized controlled clinical trial included 60 women who attended a specialized university clinic in Tabriz. Participants were randomly assigned to either the sertraline with propranolol group (n = 30) or the sertraline with propranolol placebo group (n = 30) using block randomization method. Both groups received drugs for four weeks. Data were collected using the Panic Disorder Severity Scale- Self-Report (PDSS-SR) and the Beck Depression Inventory-Short Form (BDI-13). The Mann-Whitney U test was employed to compare outcomes between the two groups, and Wilcoxon tests were used for within-group comparisons.

Results: Samples were enrolled from July 22, 2024, to February 11, 2025. The two groups exhibited no statistically significant differences in sociodemographic characteristics (p > 0.05). After the intervention, the mean score for the severity of panic attack symptoms in the sertraline with propranolol group was 6.6 (SD: 4.4), compared to 13.1 (SD: 5.4) in the sertraline with propranolol placebo group, indicating a statistically significant difference (P < 0.001). Additionally, the mean (SD) post-intervention depression score was 8.9 (4.8) in the sertraline with propranolol group and 15.5 (7.2) in the sertraline with propranolol placebo group, with the sertraline with propranolol group demonstrating a significantly lower mean depression score according to the Mann-Whitney U test (p = 0.001). Within-group comparisons also revealed a significant reduction in the severity scores for both panic attack symptoms and depression in the sertraline with propranolol group (P < 0.001).

Conclusion: Based on the results of this trial, using propranolol alongside sertraline reduces the severity of panic attacks. Given these promising results, further studies in various settings are recommended to provide high-certainty evidence in this field.

Trial registration: Iranian Registry of Clinical Trials (IRCT): IRCT20120718010324N70. Date of registration: 2022-08-31; URL: https://irct.behdasht.gov.ir/user/trial/65033/view .

Keywords: Depression; Panic attacks; Propranolol; Sertraline.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This trial was approved by the Committee of Medical Ethics of Tabriz University of Medical Sciences (Ethical code: IR.TBZMED.REC.1401.341) and registered at the Iranian Center for Clinical Trial with the IRCT20120718010324N70 code (31/08/2022). We obtained informed written consent from all participants before their recruitment. We designed and conducted this study following the Helsinki Declaration. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flow chart of the study
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Kocsis RN. Book review: diagnostic and statistical manual of mental disorders: (DSM-5). Los Angeles, CA: In.: Sage Publications Sage CA; 2013.
    1. El Khoudary SR, Greendale G, Crawford SL, Avis NE, Brooks MM, Thurston RC, Karvonen-Gutierrez C, Waetjen LE, Matthews K. The menopause transition and women’s health at midlife: a progress report from the Study of Women’s Health Across the Nation (SWAN). Menopause (New York, NY) 2019, 26(10):1213–1227. - PMC - PubMed
    1. Moghani SS, Simbar M, Fakari FR, Ghasemi V, Dolatian M, Golmakani N. Nasiri MJSJoHN, Faculty-ISSN M: The relationship between stress, anxiety and depression with menopausal women experiences. 2018, 2008:2819.
    1. Pauls DL, Noyes R Jr., Crowe RR. The Familial prevalence in second-degree relatives of patients with anxiety neurosis (panic disorder). J Affect Disord. 1979;1(4):279–85. - PubMed
    1. Smoller JW, Pollack MH, Wassertheil-Smoller S, Barton B, Hendrix SL, Jackson RD, Dicken T, Oberman A. Sheps DSJAoim: Prevalence and correlates of panic attacks in postmenopausal women: results from an ancillary study to the Women’s Health Initiative. 2003, 163(17):2041–50. - PubMed

LinkOut - more resources